Sernova Corp.
TSX:SVA.TOBiotechnology
-$0.01 today
- Market cap
- $50.98M
- Beta
- 0.66
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$0.03
Volume 0.55M
Average 0.12M
SVA.TO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Sernova Corp.TSX: SVA.TO
Stock-Based Compensation · Q2 FY2026 · quarter ended Apr 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of CA$619.48K rose 13.7% year over year, behind the +51.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 53.4% from the prior quarter. Over 3 fiscal years it compounded at -32.4% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +13.7% toward the trailing-twelve-month pace of +51.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
CAD · from the cash flow
- Latest · FY2025
- 2.3M CAD
- Year-over-year change
- +31.9%
- 4-year CAGR
- +80.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 2.3M | +31.9% |
| FY2024 | 2024-10-31 | 1.75M | -55.3% |
| FY2023 | 2023-10-31 | 3.9M | -47.6% |
| FY2022 | 2022-10-31 | 7.45M | +3311.7% |
| FY2021 | 2021-10-31 | 218.4K | — |
Stock-Based Compensation vs competitors
How SVA.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +51.2% is the highest of 2, against a peer median of +30.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | CA$2.06M CAD | +51.2% | -32.4% | — | |
| LTM Apr 2026 | $1.01M USD | +30.4% | — | — | |
| Peer median (excluding SVA.TO) | — | +30.4% | — | — | |
Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (6.97M) | (24.42M) | (39M) | (32.19M) | (15.74M) |
| Depreciation & Amortization | 267.2K | 440K | 445.55K | 540.28K | 342.59K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (70K) |
| Stock-Based Compensation | 218.4K | 7.45M | 3.9M | 1.75M | 2.3M |
| Change in Working Capital | 517.56K | 2.95M | 4.99M | 11.16M | 1.74M |
| Accounts Receivables | (89.8K) | (195.04K) | 229.7K | 561.85K | 175.47K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 607.35K | 3.14M | 4.76M | 10.6M | 1.56M |
| Other Non-Cash Items | (881.36K) | (838.57K) | (676.34K) | (150.48K) | 523.74K |
| Operating Cash Flow | (6.84M) | (14.42M) | (30.34M) | (18.9M) | (10.91M) |
| Capital Expenditures | (17.23K) | (329K) | (99.26K) | 0 | (3) |
| Acquisitions (Net) | 0 | 46M | 0 | 0 | 24.96K |
| Purchases of Investments | 0 | (59M) | (18.05M) | 0 | 0 |
| Sales of Investments | 0 | 13M | 52.97M | 11.08M | 0 |
| Other Investing Activities | (211.55K) | (46.01M) | (35.3K) | 35.3K | 0 |
| Investing Cash Flow | (228.78K) | (46.34M) | 34.78M | 11.12M | 24.96K |
| Debt Repayment | (28K) | (168.56K) | (171.93K) | (169.23K) | 4.94M |
| Common Stock Issued | 21.13M | 20.28M | 0 | 4.96M | 248.64K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.9M | 16.55M | 675.39K | 277.17K | (47.93K) |
| Financing Cash Flow | 31M | 36.66M | 503.46K | 5.07M | 5.14M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 23.92M | (24.1M) | 4.95M | (2.71M) | (5.75M) |
| Free Cash Flow | (6.86M) | (14.75M) | (30.44M) | (18.9M) | (10.91M) |
Sernova Corp.
TSX:SVA.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.